FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lympho
The FDA approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. The FDA granted approval of Yescarta to Kite Pharma. October 18, 2017